Current Report Filing (8-k)
December 07 2020 - 9:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 4,
2020
AzurRx BioPharma, Inc.
(Exact Name of Registrant as Specified in
Charter)
|
|
|
|
|
Delaware
|
|
021-214723
|
|
46-4993860
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1615 South
Congress Avenue, Suite 103
Delray Beach, Florida 33445
(Address of Principal Executive Offices, and Zip Code)
(646) 699-7855
Registrant’s Telephone Number, Including Area
Code
Not Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AZRX
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2 of this
chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
As
previously reported, on March 23, 2020, AzurRx BioPharma, Inc. (the
“Company”) received a letter from the Listing
Qualifications Department (the “Staff”) of The Nasdaq
Stock Market LLC (“Nasdaq”) indicating that, based upon
the closing bid price of the Company’s common stock, par
value $0.0001 per share (the “Common Stock”) for the
prior 30 consecutive business days, the Company was not in
compliance with the requirement to maintain a minimum bid price of
$1.00 per share for continued listing on the Nasdaq Capital Market,
as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”). The 180-day time period for the
Company to regain compliance was subsequently extended to December
3, 2020, pursuant to certain COVID-19 related relief from
price-based continued listing requirements issued by Nasdaq on
April 16, 2020.
On
November 23, 2020, the Company submitted a request to Nasdaq for a
180-day extension to regain compliance with the Minimum Bid Price
Requirement. On December 4, 2020, the Company received a letter
from Nasdaq advising that the Company had been granted a 180-day
extension to June 1, 2021 to regain compliance with the Minimum Bid
Price Requirement, in accordance with Nasdaq Listing Rule
5810(c)(3)(A).
The
Company will continue to monitor the closing bid price of its
Common Stock and seek to regain compliance with the Minimum Bid
Price Requirement within the allotted compliance period. If the
Company does not regain compliance within the allotted compliance
period, Nasdaq will provide notice that the Company’s Common
Stock will be subject to delisting. The Company would then be
entitled to appeal that determination to a Nasdaq hearings panel.
There can be no assurance that the Company will regain compliance
with the Minimum Bid Price Requirement during the 180-day
extension.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
December
7, 2020
|
AzurRx BioPharma, Inc.
By:
/s/
James Sapirstein
Name:
James Sapirstein
Title:
President and Chief Executive Officer
|
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Sep 2023 to Sep 2024